Ying-Jie Su

Ying-Jie Su

Auto-generated profile, based on publicly available information

Ying-Jie Su

Department of Pharmacy, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 January 2025 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
JFJie Fu
Jie Fu
YYYi-Dan Yan
Yi-Dan Yan
XWXu Wan
Xu Wan
XSXiao-Fan Sun
Xiao-Fan Sun
XMXiumei Ma
Xiumei Ma
YSYing-Jie Su
Ying-Jie Su
Objective: PD-1/PD-L1 inhibitors are novel immunotherapeutic agents that have been approved for first-line treatment in advanced non-small cell lung cancer (NSCLC). This study aims to evaluate the efficacy and safety of PD-1/PD-L1 inhibitors, which have completed phase 3 clinical trials, as a first-line treatment in patients with advanced NSCLC.Materials and methods: A systematic search of PubMed, Embase and the Cochrane Library was performed to extract eligible literature up to October 2023. Findings included overall survival (OS), objective response rate (ORR), progression-free survival (PFS), and grade ≥3 treatment-related adverse events (TRAEs). Furthermore, subgroup analyses were conducted based on PD-L1 expression levels and histological type.Results: We analyzed 29 studies including 18,885 patients. In analyses of all patients, penpulimab plus chemotherapy led the way for OS (HR 0.55, 95% CI: 0.40–0.75) and PFS (HR 0.43, 95% CI: 0.27–0.67). Regarding OS, for patients with PD-L1 expression ≥50%, 1%–49% and <1%, camrelizumab + chemotherapy (HR 0.48, 95% CI: 0.21–1.11), cemiplimab + chemotherapy (HR 0.50, 95% CI: 0.32–0.79) and nivolumab + ipilimumab (HR 0.64, 95% CI: 0.51–0.81) were considered optimal treatments. Compared with chemotherapy, monotherapy with nivolumab, cemiplimab, pembrolizumab, atezolizumab and durvalumab had lower odds of TRAE grade ≥3.Conclusion: In all patients, penpulimab plus chemotherapy was the most effective therapy, but treatment preferences varied by PD-L1 expression, histology type and associated outcomes. Safety at the individual patient level must be a high priority in the decision-making process. Further validation is warranted.

16 November 2022 in International Journal of Clinical Pharmacy
Verified
Journal Article
Closed access
PDF file
YYYi-Dan Yan
Yi-Dan Yan
JFJie Fu
Jie Fu
ZGZhi-Chun Gu
Zhi-Chun Gu
JLJin-Song Lu
Jin-Song Lu
YSYing-Jie Su
Ying-Jie Su
HLHou-Wen Lin
Hou-Wen Lin